Cantor Fitzgerald Brokers Lift Earnings Estimates for ATXS

Key Points

• Cantor Fitzgerald has increased its FY2025 earnings per share estimate for Astria Therapeutics to ($2.04) from the previous ($2.38), maintaining an Overweight rating with a target price of $47.00.
• In its latest earnings report, Astria Therapeutics reported an EPS of ($0.57), exceeding the consensus estimate of ($0.61) by $0.04.
• Institutional investors control nearly 99% of the company's stock, with significant increases in holdings from several hedge funds in recent quarters.

Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Equities research analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for Astria Therapeutics in a report issued on Wednesday, August 13th. Cantor Fitzgerald analyst S. Seedhouse now forecasts that the biotechnology company will post earnings per share of ($2.04) for the year, up from their previous forecast of ($2.38). Cantor Fitzgerald currently has a "Overweight" rating and a $47.00 target price on the stock. The consensus estimate for Astria Therapeutics' current full-year earnings is ($1.65) per share. Cantor Fitzgerald also issued estimates for Astria Therapeutics' FY2026 earnings at ($2.34) EPS.

A number of other brokerages have also commented on ATXS. HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Wednesday, August 13th. JMP Securities raised their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock a "market outperform" rating in a report on Wednesday, August 13th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Astria Therapeutics in a research report on Wednesday, August 13th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $29.00.

Astria Therapeutics Price Performance

NASDAQ ATXS traded down $0.07 during trading hours on Friday, hitting $6.78. The company's stock had a trading volume of 232,942 shares, compared to its average volume of 248,389. The company has a market cap of $382.66 million, a P/E ratio of -3.37 and a beta of 0.48. The company's 50 day simple moving average is $6.25 and its two-hundred day simple moving average is $5.73. Astria Therapeutics has a 12 month low of $3.56 and a 12 month high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.04.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Vestal Point Capital LP boosted its stake in shares of Astria Therapeutics by 8.2% during the 2nd quarter. Vestal Point Capital LP now owns 4,522,000 shares of the biotechnology company's stock worth $24,238,000 after acquiring an additional 342,000 shares during the last quarter. Fcpm Iii Services B.V. bought a new position in Astria Therapeutics in the 4th quarter worth $25,680,000. JPMorgan Chase & Co. lifted its position in Astria Therapeutics by 4,607.1% during the second quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company's stock valued at $9,091,000 after purchasing an additional 1,660,039 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in Astria Therapeutics by 59.7% during the second quarter. Nantahala Capital Management LLC now owns 1,069,530 shares of the biotechnology company's stock valued at $5,733,000 after purchasing an additional 400,000 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its position in Astria Therapeutics by 48.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 875,000 shares of the biotechnology company's stock worth $4,690,000 after buying an additional 286,800 shares in the last quarter. 98.98% of the stock is currently owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.